Ocular Therapeutix, Inc.
OCUL
$6.93
-$0.07-1.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -37.37% | 10.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -37.37% | 10.74% | |||
| Cost of Revenue | 4.50% | 9.33% | |||
| Gross Profit | -32.96% | -8.40% | |||
| SG&A Expenses | 19.88% | 11.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.28% | 10.15% | |||
| Operating Income | -26.38% | -9.95% | |||
| Income Before Tax | -32.37% | -32.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.37% | -32.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.37% | -32.60% | |||
| EBIT | -26.38% | -9.95% | |||
| EBITDA | -26.83% | -10.18% | |||
| EPS Basic | -31.28% | -31.81% | |||
| Normalized Basic EPS | -31.28% | -31.77% | |||
| EPS Diluted | -31.94% | -30.91% | |||
| Normalized Diluted EPS | -31.28% | -31.77% | |||
| Average Basic Shares Outstanding | 0.82% | 0.61% | |||
| Average Diluted Shares Outstanding | 0.82% | 0.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||